References
- 1. Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD guidelines: A review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93(10): 1488–1502.10.1016/j.mayocp.2018.05.02630286833
- 2. Barbu C, Iordache M, Man MG. Inflammation in COPD: Pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011;52(1): 21–27.
- 3. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: The role of exacerbations. Proc Am Thorac Soc. 2007;4(8): 626–634.10.1513/pats.200706-071TH18073394
- 4. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: The evolving clinical challenge. Chest. 2012;141(2): 396–3405.10.1378/chest.11-049521835899
- 5. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2): 81–89.10.1513/AnnalsATS.201208-043OC23607835
- 6. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;48(5): 531–539.10.1165/rcmb.2012-0492TR23328639
- 7. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1): 16–27.10.1016/j.jaci.2016.05.01127373322
- 8. Zhou X, Li Q, Zhou X. Exacerbation of chronic obstructive pulmonary disease. Cell Biochem Biophys. 2015;73(2): 349–355.10.1007/s12013-015-0605-9709237527352322
- 9. Pascual-Gonzalez Y, Lopez-Sanchez M, Dorca J, Santos S. Defining the role of neutrophil-to-lymphocyte ratio in COPD: A systematic literature review. Int J Chron Obstruct Pulmon Dis. 2018;13: 3651–3662.10.2147/COPD.S178068622585430464448
- 10. Bialas AJ, Pedone C, Piotrowski WJ, Incalzi RA. Platelet distribution width as a prognostic factor in patients with COPD - pilot study. Int J Chron Obstruct Pulmon Dis. 2017;12: 2261–2267.10.2147/COPD.S131868554658828814854
- 11. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. J Thromb Haemost. 2010;8(1): 148–156.10.1111/j.1538-7836.2009.03584.x375549619691485
- 12. Biljak VR, Pancirov D, Cepelak I, Popovic-Grle S, Stjepanovic G, Grubisic TZ. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22(6): 466–470.10.3109/09537104.2011.57388721506665
- 13. Steiropoulos P, Papanas N, Nena E, Xanthoudaki M, Goula T, Froudarakis M, et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: The role of comorbidities. Angiology. 2013;64(7): 535–539.10.1177/000331971246143623052724
- 14. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): A population based study. Thorax. 2004;59(10): 892–896.10.1136/thx.2003.015768174682815454657
- 15. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, Veer CV, Buurman WA, et al. Systemic anti-inflammatory mediators in COPD: Increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001;56(9): 721–726.10.1136/thx.56.9.721
- 16. Burge S, Wedzicha JA. COPD exacerbations: Definitions and classifications. Eur Respir J. 2003;21(41 suppl): 46s–53s.10.1183/09031936.03.0007800212795331
- 17. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(12): 1298–1303.10.1164/rccm.200310-1443OC14990395
- 18. Rodriguez-Roisin R. COPD exacerbations 5: Management. Thorax. 2006;61(6): 535–544.10.1136/thx.2005.041863211121916738044
- 19. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11): 925–931.10.1136/thx.2005.040527174723516055622
- 20. Tanriverdi H, Ornek T, Erboy F, Altinsoy B, Uygur F, Atalay F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr. 2015;127(19): 756–763.10.1007/s00508-014-0690-625586444
- 21. In E, Kuluozturk M, Oner O, Deveci F. The importance of neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease. Turk Thorac J. 2016;17(2): 41–46.10.5578/ttj.17.2.009579211529404122
- 22. Gunay E, Ulasli SS, Akar O, Ahsen A, Gunay S, Koyuncu T, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: A retrospective study. Inflammation. 2014;37(2): 374–380.10.1007/s10753-013-9749-124078279
- 23. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: A simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1): 28–32.
- 24. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: A link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1): 47–58.10.2174/13816121179504980421247392
- 25. Agapakis DI, Massa EV, Hantzis I, Maraslis S, Alexiou E, Imprialos KP, et al. The role of mean platelet volume in chronic obstructive pulmonary disease exacerbation. Respir Care. 2016;61(1): 44–49.10.4187/respcare.0413226604328
- 26. Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8): 1244–1248.10.1111/resp.1214323786593
- 27. Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122(6): 284–290.10.20452/pamw.128422576316
- 28. Makhlouf HA, Sadek SH, Nafady AA. Platelet function in diabetic and nondiabetic patients with chronic obstructive pulmonary disease: A case control study. Clin Respir J. 2018;12(1): 48–56.10.1111/crj.1247727003100
- 29. Bansal R, Gupta HL, Goel A, Yadav M. Association of increased platelet volume in patients of chronic obstructive pulmonary disease: Clinical implications. J Indian Acad Clin Med. 2002;3(2): 169–172.
- 30. Bessman JD, Williams LJ, Gilmer PR, Jr. Platelet size in health and hematologic disease. Am J Clin Pathol. 1982;78(2): 150–153.10.1093/ajcp/78.2.1506954850
- 31. Yohannes AM, Ershler WB. Anemia in COPD: A systematic review of the prevalence, quality of life, and mortality. Respir Care. 2011;56(5): 644–652.10.4187/respcare.0100221276321
- 32. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26(2): 234–241.10.1183/09031936.05.0002480416055870
- 33. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2): 459–467.10.1378/chest.124.2.45912907529
- 34. Shafiek H, Abd-elwahab N, Baddour M, Degady A, El-hoffy M. Outcome predictors of severe acute exacerbation of chronic obstructive pulmonary disease: Role of inflammatory biomarkers. Int J Respir Pulm Med. 2016;3(2): 047.10.23937/2378-3516/1410047